Table 1 Most common pimasertib-related TEAEs (incidence ⩾10% in any regimen; safety analysis set)
Treatment-related TEAEs | Regimen 1 (N=33) | Regimen 2 (N=32) | Regimen 3 (N=15) | |||
|---|---|---|---|---|---|---|
Patients with at least one event, n (%) | 25 (75.8) | 21 (65.6) | 14 (93.3) | |||
Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | |
Diarrhea | 10 (30.3) | – | 12 (34.4) | 1 (3.1) | 6 (40.0) | 3 (20.0) |
Nausea | 7 (21.2) | – | 2 (6.3) | – | 2 (13.3) | 1 (6.7) |
Vomiting | 4 (12.1) | – | 1 (3.1) | – | 2 (13.3) | 1 (6.7) |
Retinal detachment | 2 (6.1) | – | 5 (15.6) | – | 1 (6.7) | – |
Blurred vision | 4 (12.1) | – | 2 (6.3) | – | – | – |
Peripheral edema | 4 (12.1) | – | 2 (6.3) | – | 3 (20.0) | – |
Fatigue | 2 (6.1) | – | 3 (9.4) | – | 3 (20.0) | – |
Face edema | 1 (3.0) | – | 1 (3.1) | – | 3 (20.0) | – |
Skin rash | 3 (9.1) | – | 4 (12.5) | – | 4 (26.7) | – |
Hypocalcemia | – | – | 1 (3.1) | – | 2 (13.3) | – |
Hyperuricemia | – | – | – | – | 2 (13.3) | – |
AST increased | 4 (12.1) | – | 1 (3.1) | – | 1 (6.7) | 1 (6.7) |
Blood ALP increased | 2 (6.1) | 1 (3.0) | 1 (3.1) | – | 2 (13.3) | – |
